The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.

The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.

The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.

The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.

The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.

The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.

The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.

The latest price target for Harpoon Therapeutics (NASDAQ: HARP) was reported by Citigroup on September 18, 2023. The analyst firm set a price target for $33.00 expecting HARP to rise to within 12 months (a possible 693.27% upside). 10 analyst firms have reported ratings in the last year.

The latest analyst rating for Harpoon Therapeutics (NASDAQ: HARP) was provided by Citigroup, and Harpoon Therapeutics maintained their buy rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Harpoon Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Harpoon Therapeutics was filed on September 18, 2023 so you should expect the next rating to be made available sometime around September 18, 2024.

While ratings are subjective and will change, the latest Harpoon Therapeutics (HARP) rating was a maintained with a price target of $60.00 to $33.00. The current price Harpoon Therapeutics (HARP) is trading at is $4.16, which is out of the analyst’s predicted range.